This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about Anadrol-50 (oxymetholone). It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using Anadrol-50.
Course and treatment of autosomal dominant polycystic kidney disease
Diagnosis of and screening for autosomal dominant polycystic kidney disease
Extrarenal manifestations of autosomal dominant polycystic kidney disease
Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth
Hypertension in autosomal dominant polycystic kidney disease
Prenatal sonographic diagnosis of cystic renal disease
Renal manifestations of autosomal dominant polycystic kidney disease
Screening for intracranial aneurysm
Urinary tract infection in autosomal dominant polycystic kidney disease
The following organizations also provide reliable health information.
Neural injections of Bromodeoxyuridine (BrdU) were applied to males of both groups to test for neurogenesis . Analysis showed that testosterone and dihydrotestosterone regulated adult hippocampal neurogenesis (AHN). Adult hippocampal neurogenesis was regulated through the androgen receptor in the wild-type male rats, but not in the TMF male rats. To further test the role of activated androgen receptors on AHN, flutamide , an antiandrogen drug that competes with testosterone and dihydrotestosterone for androgen receptors , and dihydrotestosterone were administered to normal male rats. Dihydrotestosterone increased the number of BrdU cells, while flutamide inhibited these cells.